Retatrutide Halves Knee Pain for Two in Three Patients
Retatrutide Halves Knee Pain for Two in Three Patients
Retatrutide Halves Knee Pain for Two in Three Patients
Key points
اہم نکات
मुख्य बातें
- Eli Lilly's experimental weight-loss drug retatrutide cut knee pain by at least half in about two in three patients in two major phase 3 trials of more than 1,000 adults with knee osteoarthritis and obesity.
- Patients on the highest dose lost about a quarter of their body weight on average.
- The results were published on November 8 in the New England Journal of Medicine; the drug is still experimental and not yet approved, and it is not yet known whether it slows joint damage.
- Eli Lilly's experimental weight-loss drug retatrutide cut knee pain by at least half in about two in three patients in two major phase 3 trials of more than 1,000 adults with knee osteoarthritis and obesity.
- Patients on the highest dose lost about a quarter of their body weight on average.
- The results were published on November 8 in the New England Journal of Medicine; the drug is still experimental and not yet approved, and it is not yet known whether it slows joint damage.
- Eli Lilly's experimental weight-loss drug retatrutide cut knee pain by at least half in about two in three patients in two major phase 3 trials of more than 1,000 adults with knee osteoarthritis and obesity.
- Patients on the highest dose lost about a quarter of their body weight on average.
- The results were published on November 8 in the New England Journal of Medicine; the drug is still experimental and not yet approved, and it is not yet known whether it slows joint damage.
Eli Lilly's experimental weight-loss drug retatrutide cut knee pain by at least half in about two in three patients in two major phase 3 trials of more than 1,000 adults with knee osteoarthritis and obesity. Patients on the highest dose lost about a quarter of their body weight on average. The results were published on November 8 in the New England Journal of Medicine; the drug is still experimental and not yet approved, and it is not yet known whether it slows joint damage.
Eli Lilly's experimental weight-loss drug retatrutide cut knee pain by at least half in about two in three patients in two major phase 3 trials of more than 1,000 adults with knee osteoarthritis and obesity. Patients on the highest dose lost about a quarter of their body weight on average. The results were published on November 8 in the New England Journal of Medicine; the drug is still experimental and not yet approved, and it is not yet known whether it slows joint damage.
Eli Lilly's experimental weight-loss drug retatrutide cut knee pain by at least half in about two in three patients in two major phase 3 trials of more than 1,000 adults with knee osteoarthritis and obesity. Patients on the highest dose lost about a quarter of their body weight on average. The results were published on November 8 in the New England Journal of Medicine; the drug is still experimental and not yet approved, and it is not yet known whether it slows joint damage.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।